AbbVie Inc (ABBV)vsBioNTech SE (BNTX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
BNTX
BioNTech SE
$101.57
-0.48%
HEALTHCARE · Cap: $25.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2031% more annual revenue ($61.16B vs $2.87B). ABBV leads profitability with a 6.9% profit margin vs -39.6%. BNTX appears more attractively valued with a PEG of 0.05. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
BNTX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+37.4%
Fair Value
$174.59
Current Price
$101.57
$73.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Weak financial health signals
ROE of -5.9% — below average capital efficiency
Revenue declined 23.7%
Earnings declined 43.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : BNTX
The strongest argument for BNTX centers on PEG Ratio, Price/Book, Altman Z-Score. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : BNTX
The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while BNTX is a turnaround play — different risk/reward profiles.
BNTX carries more volatility with a beta of 1.59 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100). BNTX offers better value entry with a 37.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
BioNTech SE
HEALTHCARE · BIOTECHNOLOGY · USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?